166 related articles for article (PubMed ID: 36813747)
1. Safety, efficacy, and pharmacokinetics of SH-1028 in EGFR T790M-positive advanced non-small cell lung cancer patients: A dose-escalation phase 1 study.
He J; Ma P; Zhao D; Shi X; Guo R; Gao W; Shu Y
Cancer; 2023 May; 129(10):1513-1522. PubMed ID: 36813747
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study.
Shi Y; Li B; Wu L; Pan Y; Pan Z; Liu Y; Fan Y; Ji Y; Fang J; Shi Q; Shi J; Gao H; Hu Y; Wang X; He Z; Ma R; Zhang Y; Jiang D; Bai Y; Zhang Y; Huang L; Zhou T; Liu H; Wang D; Wen Q; Chen G; Zang A; Wang X; Zhang X; Hu J; Yang R; Zhang G; Gu K; Wang L; Wang Q; Wei Z; Li Z; Lu H; Zhang H; Chen H; Song T
J Thorac Oncol; 2022 Oct; 17(10):1205-1215. PubMed ID: 35659581
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors.
Lin L; Pan H; Li X; Zhao C; Sun J; Hu X; Zhang Y; Wang M; Ren X; Luo X; Shan G; Hui AM; Wu Z; Liu H; Tian L; Shi Y
Lung Cancer; 2022 Apr; 166():98-106. PubMed ID: 35248866
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study.
Shi Y; Wu S; Wang K; Cang S; Yao W; Fan Y; Wu L; Huang M; Li X; Pan Y; Yang Z; Zhu B; Chen G; Shi J; Sun M; Fang J; Wang L; Chen Z; Liu C; Li J; Liu J; Sun S; Zhao Y; Guo Y; Meng Z; Liu Z; Han Z; Lu H; Ma R; Hu S; Zhao G; Liu Z; Xie C; Zhong D; Zhao H; Yu H; Zhang L; Bi M; Yi S; Guo S; Yi T; Li W; Lin Y; Shu Y; Chen Z; Guo Z; Greco M; Wang T; Shen H
J Thorac Oncol; 2022 Nov; 17(11):1306-1317. PubMed ID: 36049654
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial.
Kim DW; Lee DH; Han JY; Lee J; Cho BC; Kang JH; Lee KH; Cho EK; Kim JS; Min YJ; Cho JY; An HJ; Kim HG; Lee KH; Kim BS; Jang IJ; Yoon S; Han O; Noh YS; Hong KY; Park K
Lung Cancer; 2019 Sep; 135():66-72. PubMed ID: 31447004
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations.
Nishio M; Murakami H; Ohe Y; Hida T; Sakai H; Kasahara K; Imamura F; Baba T; Kubota K; Hosomi Y; Shimokawa T; Hayashi H; Miyadera K; Tamura T
Invest New Drugs; 2019 Dec; 37(6):1207-1217. PubMed ID: 30790152
[TBL] [Abstract][Full Text] [Related]
7. Safety, pharmacokinetics, and efficacy of BPI-15086 in patients with EGFR T790M-mutated advanced non-small-cell lung cancer: results from a phase I, single-arm, multicenter study.
Xing P; Zheng X; Wang Y; Chu T; Wang S; Jiang J; Qian J; Han X; Ding L; Wang Y; Cui L; Li H; Li L; Chen X; Han B; Hu P; Shi Y
ESMO Open; 2022 Jun; 7(3):100473. PubMed ID: 35526510
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study.
Lu S; Zhang Y; Zhang G; Zhou J; Cang S; Cheng Y; Wu G; Cao P; Lv D; Jian H; Chen C; Jin X; Tian P; Wang K; Jiang G; Chen G; Chen Q; Zhao H; Ding C; Guo R; Sun G; Wang B; Jiang L; Liu Z; Fang J; Yang J; Zhuang W; Liu Y; Zhang J; Pan Y; Chen J; Yu Q; Zhao M; Cui J; Li D; Yi T; Yu Z; Yang Y; Zhang Y; Zhi X; Huang Y; Wu R; Chen L; Zang A; Cao L; Li Q; Li X; Song Y; Wang D; Zhang S; Ding L; Zhang L; Yuan X; Yao L; Shen Z
J Thorac Oncol; 2022 Oct; 17(10):1192-1204. PubMed ID: 35724798
[TBL] [Abstract][Full Text] [Related]
9. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial.
Yang JC; Camidge DR; Yang CT; Zhou J; Guo R; Chiu CH; Chang GC; Shiah HS; Chen Y; Wang CC; Berz D; Su WC; Yang N; Wang Z; Fang J; Chen J; Nikolinakos P; Lu Y; Pan H; Maniam A; Bazhenova L; Shirai K; Jahanzeb M; Willis M; Masood N; Chowhan N; Hsia TC; Jian H; Lu S
J Thorac Oncol; 2020 Dec; 15(12):1907-1918. PubMed ID: 32916310
[TBL] [Abstract][Full Text] [Related]
10. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T
Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163
[TBL] [Abstract][Full Text] [Related]
11. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.
Ahn MJ; Han JY; Lee KH; Kim SW; Kim DW; Lee YG; Cho EK; Kim JH; Lee GW; Lee JS; Min YJ; Kim JS; Lee SS; Kim HR; Hong MH; Ahn JS; Sun JM; Kim HT; Lee DH; Kim S; Cho BC
Lancet Oncol; 2019 Dec; 20(12):1681-1690. PubMed ID: 31587882
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial.
Xiong A; Ren S; Liu H; Miao L; Wang L; Chen J; Li W; Li R; Wang X; Lu Z; Wang D; Wu X; Liu Z; Xing L; Mao Y; Liu C; Zeng A; Niu H; Du Y; Sun Y; Pan Y; Hu Y; Zhang X; Chen X; Ma Z; Li N; Zhang J; Zhao M; Li X; Ye F; Li M; Yu G; Zhang X; Min J; Han D; Li J; Zhou C
J Thorac Oncol; 2022 Oct; 17(10):1216-1226. PubMed ID: 35798241
[TBL] [Abstract][Full Text] [Related]
13. A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors.
Cho BC; Han JY; Kim SW; Lee KH; Cho EK; Lee YG; Kim DW; Kim JH; Lee GW; Lee JS; Shim BY; Kim JS; Chun SH; Lee SS; Kim HR; Hong MH; Ahn JS; Sun JM; Lee Y; Lee DH; Kang JA; Lee N; Kwon MJ; Espenschied C; Yablonovitch A; Ahn MJ
J Thorac Oncol; 2022 Apr; 17(4):558-567. PubMed ID: 34958928
[TBL] [Abstract][Full Text] [Related]
14. Rociletinib in EGFR-mutated non-small-cell lung cancer.
Sequist LV; Soria JC; Goldman JW; Wakelee HA; Gadgeel SM; Varga A; Papadimitrakopoulou V; Solomon BJ; Oxnard GR; Dziadziuszko R; Aisner DL; Doebele RC; Galasso C; Garon EB; Heist RS; Logan J; Neal JW; Mendenhall MA; Nichols S; Piotrowska Z; Wozniak AJ; Raponi M; Karlovich CA; Jaw-Tsai S; Isaacson J; Despain D; Matheny SL; Rolfe L; Allen AR; Camidge DR
N Engl J Med; 2015 Apr; 372(18):1700-9. PubMed ID: 25923550
[TBL] [Abstract][Full Text] [Related]
15. Phase I Trial of a Third Generation EGFR Mutant-Selective Inhibitor (D-0316) in Patients with Advanced Non-Small Cell Lung Cancer.
Jian H; Wang K; Cheng Y; Ding L; Wang Y; Shi Z; Zhang L; Wang Y; Lu S
Oncologist; 2022 Mar; 27(3):163-e213. PubMed ID: 35274722
[TBL] [Abstract][Full Text] [Related]
16. Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples.
Kiura K; Yoh K; Katakami N; Nogami N; Kasahara K; Takahashi T; Okamoto I; Cantarini M; Hodge R; Uchida H
Cancer Sci; 2018 Apr; 109(4):1177-1184. PubMed ID: 29363250
[TBL] [Abstract][Full Text] [Related]
17. Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study.
Shi Y; Zhao Y; Yang S; Zhou J; Zhang L; Chen G; Fang J; Zhu B; Li X; Shu Y; Shi J; Zheng R; Wang D; Yu H; Huang J; Zhuang Z; Wu G; Zhang L; Guo Z; Greco M; Li X; Zhang Y
J Thorac Oncol; 2022 May; 17(5):708-717. PubMed ID: 35181498
[TBL] [Abstract][Full Text] [Related]
18. A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.
Sa H; Shi Y; Ding C; Ma K
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7729-7742. PubMed ID: 37004599
[TBL] [Abstract][Full Text] [Related]
19. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
[TBL] [Abstract][Full Text] [Related]
20. First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance.
Ma Y; Zheng X; Zhao H; Fang W; Zhang Y; Ge J; Wang L; Wang W; Jiang J; Chuai S; Zhang Z; Xu W; Xu X; Hu P; Zhang L
J Thorac Oncol; 2018 Jul; 13(7):968-977. PubMed ID: 29626621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
